



**LABORATORY REPORT**

NAME : ██████████ REFERRED BY : ..... VISIT NO : ██████████  
 AGE : ██████████ COLLECTED ON : ██████████  
 GENDER : ██████████ LAB MR# : ██████████ RECEIVED ON : ██████████ 51  
 OP / IP / DG # : APPROVED ON : ██████████  
 REPORT STATUS : Final Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

Amfit Senior Citizen- Female

**HAEMATOLOGY**

**Complete Blood Counts** (Whole Blood - EDTA)

(Automated Hematology Analyzer & Microscopy)

Total Leukocyte Count <i>coulter principle</i>	6.6	4.0 - 10.0	10 <sup>3</sup> /μl
RBC Count <i>coulter principle</i>	4.1	3.8 - 4.8	10 <sup>6</sup> /μL
Hemoglobin <i>photometric method</i>	<b>11.8 L</b>	13.0 - 17.0	g/dL
Hematocrit	<b>35.7 L</b>	40 - 50	%
MCV(Mean Corpuscular Volume) <i>Derived from RBC Histogram</i>	87.8	83 - 101	fL
MCH(Mean Corpuscular Hemoglobin) <i>Calculated</i>	28.9	27 - 32	pg
MCHC(Mean Corpuscular Hemoglobin Concentration) <i>Calculated</i>	33.0	31.5 - 34.5	g/dL
RDW <i>Derived from RBC Histogram</i>	14.0	11.6 - 14	%
Platelet Count <i>coulter principle</i>	253	150 - 410	10 <sup>3</sup> /μl
MPV	8.2	7.5 - 11.5	fL

**Differential count % (VCSn Technology & light microscopy)**

Neutrophils	58.0	40-80%	%
Lymphocytes	33.0	20-40%	%
Monocytes	6.0	2-10%	%
Eosinophils	3.0	1-6%	%
Basophils	0.0	0-1%	%

**Differential Counts, Absolute(calculated)**

Absolute Neutrophil Count	3.83	2.0-7.0	10 <sup>3</sup> /μl
Absolute Lymphocyte Count	2.18	1.0-3.0	10 <sup>3</sup> /μl
Absolute Monocyte Count	0.40	0.2 - 1.0	10 <sup>3</sup> /μl
Absolute Eosinophil Count (AEC)	0.20	0.02 - 0.5	10 <sup>3</sup> /μl
Absolute Basophil Count	0.00	0.02 - 0.1	10 <sup>3</sup> /μl





**LABORATORY REPORT**

<b>NAME</b> :	██████████	<b>REFERRED BY</b> :	.....	<b>VISIT NO</b> :	██████████
<b>AGE</b> :	██████████		████████████████████	<b>COLLECTED ON</b> :	██████████
<b>GENDER</b> :	██████████	<b>LAB MR#</b> :	██████████	<b>RECEIVED ON</b> :	██████████
<b>OP / IP / DG #</b> :				<b>APPROVED ON</b> :	██████████
				<b>REPORT STATUS</b> :	Final Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

**Amfit Senior Citizen- Female**

**BIOCHEMISTRY**

**Lipid profile (Serum)**

Cholesterol Total - Serum <i>Enzymatic colorimetric</i>	127.0	No risk: <200 Moderate risk: 200-239 High risk: >240	mg/dL
Triglycerides <i>Enzymatic colorimetry</i>	99.9	Normal: <150 Borderline-high: 150–199 High risk 200–499 Very high risk >500	mg/dL
Cholesterol - HDL (Direct) <i>Enzymatic colorimetric</i>	<b>29.0 L</b>	High Risk: <40 No Risk: >60	mg/dL
LDL Chol, Calculated	78.02	<100	mg/dL
VLDL (Very Low Density Lipoprotein) <i>Calculation</i>	20.0	<30	mg/dL
Cho/HDL Ratio <i>Enzymatic colorimetric &amp; Calculation</i>	<b>4.38 H</b>	Normal:<4.0 Low risk:4.0-6.0 High risk:>6.0	
LDL/HDL Ratio	3.20	Desirable/Low Risk: 0.5 - 3.0 Borderline/Moderate: 3.1 - 6.0 High Risk: >6.0	

**LFT(Bilirubin Total, Bilirubin Conjugated, (Serum)**

Bilirubin Total <i>Diazo method</i>	0.26	<1.1	mg/dL
Bilirubin Conjugated <i>Diazo method</i>	0.12	<=0.2	mg/dL
Bilirubin Unconjugated, Indirect <i>Calculation</i>	0.14	<1.0	mg/dL
Aspartate Aminotransferase (AST/SGOT) <i>IFCC kinetic</i>	12	<31	U/L
Alanine aminotransferase - (ALT / SGPT) <i>Kinetic IFCC</i>	10	<33	U/L
Alkaline Phosphatase - ALP <i>IFCC kinetic</i>	70.0	<129	U/L

**Interpretation:**

1. In an asymptomatic patient, Non alcoholic fatty liver disease (NAFLD) is the most common cause of increased AST, ALT levels. NAFLD is considered as hepatic manifestation of metabolic syndrome.
2. In most type of liver disease, ALT activity is higher than that of AST; exception may be seen in Alcoholic Hepatitis,

This is an electronically authenticated laboratory report.

Page 2 of 11





**LABORATORY REPORT**

<b>NAME</b> :	██████████	<b>REFERRED BY</b> :	.....	<b>VISIT NO</b> :	██████████
<b>AGE</b> :	██████████		██	<b>COLLECTED ON</b> :	██████████
<b>GENDER</b> :	Female	<b>LAB MR#</b> :	██████████	<b>RECEIVED ON</b> :	██████████
<b>OP / IP / DG #</b> :				<b>APPROVED ON</b> :	██████████
				<b>REPORT STATUS</b> :	Final Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

**Amfit Senior Citizen- Female**

Hepatic Cirrhosis, and Liver neoplasia. In a patient with Chronic liver disease, AST:ALT ratio>1 is highly suggestive of advanced liver fibrosis.  
 3. In known cases of Chronic Liver disease due to Viral Hepatitis B & C, Alcoholic liver disease or NAFLD, Enhanced liver fibrosis (ELF) test may be used to evaluate liver fibrosis.  
 4. In a patient with Chronic Liver disease, AFP and Des-gamma carboxyprothrombin (DCP)/PIVKA II can be used to assess risk for development of Hepatocellular Carcinoma.

**Blood Urea Nitrogen, BUN - Serum (Serum)**

Blood Urea Nitrogen (BUN) <i>Calculation</i>	<b>6.45 L</b>	7-19	mg/dL
---	---------------	------	-------

**Creatinine (Serum)**

Creatinine <i>Modified Jaffe Kinetic</i>	0.66	< 1.20	mg/dL
---	------	--------	-------

**Urea (Serum)**

Urea <i>Kinetic, Urease</i>	<b>13.8 L</b>	16 - 38	mg/dL
--------------------------------	---------------	---------	-------

**Uric acid (Serum)**

Uric acid <i>Uricase</i>	4.9	3.4-7	mg/dL
-----------------------------	-----	-------	-------

This is an electronically authenticated laboratory report.

Page 3 of 11





**LABORATORY REPORT**

<b>NAME</b> :	██████████	<b>REFERRED BY</b> :	.....	<b>VISIT NO</b> :	██████████
<b>AGE</b> :	██████████		████████████████████	<b>COLLECTED ON</b> :	██████████
<b>GENDER</b> :	██████	<b>LAB MR#</b> :	██████████	<b>RECEIVED ON</b> :	██████████
<b>OP / IP / DG #</b> :				<b>APPROVED ON</b> :	██████████
				<b>REPORT STATUS</b> :	Final Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

Amfit Senior Citizen- Female

**CLINICAL PATHOLOGY**

**Urine Examination - Routine & Microscopy (CUE) (Urine)**

**PHYSICAL EXAMINATION:**

Volume	15.00		mL
Colour	Pale yellow	Pale	
Appearance	Clear	Clear	

**CHEMICAL EXAMINATION:**

pH	5.00	4.8 - 7.4	
<i>Dip stick</i>			
Specific Gravity	<b>1.025 H</b>	1.010 - 1.022	
<i>Dip Stick (Bromothymol blue)</i>			
Protein	Negative	Negative	
<i>Dip Stick/ Sulfosalicylic acid</i>			
Glucose	Negative	Negative	
<i>Dip Stick /Benedicts test</i>			
Ketones	Negative	Negative	
<i>Dip stick/Sodium nitroprusside reaction</i>			
Urobilinogen	Normal	Normal	
<i>Dip Stick / Ehrlich reaction</i>			
Leucocyte Esterase	Negative	Negative	
<i>Dip Stick</i>			
Nitrite	Negative	Negative	
<i>Dip Stick / (Griess test )</i>			
Bilirubin	Negative	Negative	
<i>Dipstick/diazo</i>			
Blood	Negative	Negative	
<i>Dip Stick ( Peroxidase)</i>			

**Microscopic Examination**

Pus Cells	1-2	0 - 5	/HPF
Epithelial Cells	1-2	< 5	/HPF
RBCs	Absent	0 - 5	/HPF
Casts	Absent	Absent	/LPF
Crystals	Absent	Absent	/HPF

This is an electronically authenticated laboratory report.

Page 4 of 11





**LABORATORY REPORT**

<b>NAME</b> :	██████████	<b>REFERRED BY</b> :	.....	<b>VISIT NO</b> :	██████████
<b>AGE</b> :	██████████		██	<b>COLLECTED ON</b> :	██████████00
<b>GENDER</b> :	██████████	<b>LAB MR#</b> :	██████████	<b>RECEIVED ON</b> :	██████████
<b>OP / IP / DG #</b> :				<b>APPROVED ON</b> :	██████████
				<b>REPORT STATUS</b> :	Final Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

**Amfit Senior Citizen- Female**

**BIOCHEMISTRY**

**Calcium - Serum (Serum)**

Calcium - Serum NM-BAPTA	9.50	8.6 - 10.0	mg/dL
-----------------------------	------	------------	-------

**Vitamin B12 (Serum)**

Vitamin B12 ECLIA	<b>163.5 L</b>	191-771	pg/mL
----------------------	----------------	---------	-------

**Interpretation:**

Vitamin B12 also referred to as cobalamin is a water soluble vitamin. The uptake in the gastro intestinal track depends on intrinsic factor, which is synthesised by gastric parietal cells

**Deficiency state:**

- >Lack of intrinsic factor due to autoimmune atrophic gastritis
- >Mal-absorption due to gastrostomy
- >Inflammatory bowel disease
- >Dietary deficiency (strict vegans)
- >Vit B12 deficiency results in megaloblastic anaemia, peripheral neuropathy, dementia and depression

**Increased levels:**

- >VIT B12 supplement intake
- >Polycythaemia Vera.

**Vitamin D, 25-Hydroxy (Serum)**

Vitamin D, 25-Hydroxy ECLIA	<b>17.0 L</b>	Deficient: <=20 Insufficiency: 20-29 Desirable: >=30-100 Toxicity: >100	ng/ml
--------------------------------	---------------	--	-------

**Interpretation:**

Vitamin D is a fat soluble vitamin produced in the skin by exposure to sun light. Deficiency in children causes rickets and in adults leads to osteomalacia

**Decreased levels:**

- >Impaired cutaneous production (lack of sunlight exposure)
- >Dietary absence
- >Malabsorption
- >Increased metabolism due to drugs like barbiturates, phenytoin.
- >Liver disease
- >Renal failure
- >VIT D receptor mutation

**Increased levels:**

- >Vitamin D intoxication due to increased vit D supplements intake

**HbA1c - Glycated Hemoglobin (Whole Blood - EDTA)**

██████████

This is an electronically authenticated laboratory report.





**LABORATORY REPORT**

<b>NAME</b> : [REDACTED]	<b>REFERRED BY</b> : [REDACTED]	<b>VISIT NO</b> : [REDACTED]
<b>AGE</b> : [REDACTED]	[REDACTED]	<b>COLLECTED ON</b> : [REDACTED]
<b>GENDER</b> : [REDACTED]	<b>LAB MR#</b> : [REDACTED]	<b>RECEIVED ON</b> : [REDACTED]
<b>OP / IP / DG #</b> :		<b>APPROVED ON</b> : [REDACTED]
		<b>REPORT STATUS</b> : Final Report



Test Name	Result	Biological Ref. Interval	Unit
<b>Amfit Senior Citizen- Female</b>			
Glycated Hemoglobin, HbA1c <i>TINIA</i>	5.30	Non diabetic range: 4.8-5.6 Prediabetic range: 5.7-6.4% Diabetes range: >=6.5%	%
Estimated Average Glucose	105.4		mg/dL

**Interpretation:**

Note: HbA1c results may vary in situations of abnormal red cell turnover, such as pregnancy, recent blood loss or transfusion, or some anemias. In such cases only blood glucose criteria should be used to diagnose diabetes (ADA, 2014). Please correlate clinically.

**Glucose - Fasting (Fluoride Plasma - F)**

Glucose - Fasting <i>Hexokinase</i>	<b>118.0 H</b>	Normal : 74-100 Pre-diabetic : 100-125 Diabetic: >=126	mg/dL
--	----------------	--	-------

**T3 - Total (Tri Iodothyronine) (Serum)**

T3 - Total (Tri Iodothyronine) <i>ECLIA</i>	118.8	80.00 - 200.00	ng/dL
--	-------	----------------	-------

**T4 - Total (Thyroxine - Total) (Serum)**

T4 - Total (Thyroxine - Total) <i>ECLIA</i>	9.73	5.1-14.1	µg/dL
--	------	----------	-------

**Interpretation:**

- Note :**
- Total T3 & T4 levels measure the hormone which is in the bound form and is not available to most tissues.
  - Severe systemic illness affects the thyroid binding proteins and can falsely alter Total T 4 levels in the absence of a primary thyroid disease. Hence Free T3 & T4 levels are recommended for accurate assessment of thyroid dysfunction.

**TSH, Thyroid Stimulating Hormone (Serum)**


TSH, Thyroid Stimulating Hormone <i>ECLIA</i>	2.060	Non pregnant women: 0.27-4.2 Pregnant women 1st trimester: 0.1-2.5 2nd trimester: 0.2-3.0 3rd trimester: 0.3-3.0	µIU/mL
--	-------	--	--------

**Interpretation:**

- The following potential sources of variation should be considered while interpreting thyroid hormone results:
- Circadian variation in TSH secretion: peak levels are seen between 2-4 am. Minimum levels seen between 6-10 am. This variation may be as much as 50% thus, influence of sampling time needs to be considered for clinical interpretation.
  - Total T3 and T4 levels are seen to have physiological rise during pregnancy and in patients on steroid treatment

This is an electronically authenticated laboratory report.





**LABORATORY REPORT**

NAME	: [REDACTED]	REFERRED BY	: [REDACTED]	VISIT NO	: [REDACTED]
AGE	: [REDACTED]			COLLECTED ON	: [REDACTED] 00
GENDER	: [REDACTED]	LAB MR#	: [REDACTED]	RECEIVED ON	: [REDACTED]
OP / IP / DG #	:			APPROVED ON	: [REDACTED]
				REPORT STATUS	: Final Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

**Amfit Senior Citizen- Female**

3. Circulating forms of T3 and T4 are mostly reversibly bound with Thyroxine binding globulins (TBG), and to a lesser extent with albumin and Thyroid binding Pre-Albumin. Thus the conditions in which TBG and protein levels alter such as chronic liver disorders, pregnancy, excess of estrogens, androgens, anabolic steroids and glucocorticoids may cause misleading total T3, total T4 and TSH interpretations.
  4. T4 may be normal in the presence of hyperthyroidism under the following conditions : T3 thyrotoxicosis, Hypoproteinemia related reduced binding, in presence of drugs (eg Phenytoin, Salicylates etc)
  5. Neonates and infants have higher levels of T4 due to increased concentration of TBG
  6. TSH levels may be normal in central hypothyroidism, recent rapid correction of hypothyroidism or hyperthyroidism, pregnancy, phenytoin therapy etc.
  7. TSH values of <0.03 uIU/mL must be clinically correlated to evaluate the presence of a rare TSH variant in certain individuals which is undetected by conventional methods.
  8. Presence of Autoimmune disorders may lead to spurious results of thyroid hormones
  9. Various drugs can lead to interference in test results
- It is recommended to evaluate unbound fractions, that is free T3 (fT3) and free T4 (fT4) for clinic-pathologic correlation, as these are the metabolically active forms.

**Iron Binding Capacity - Total (TIBC) (Serum)**

Iron	<b>34.2 L</b>	59-158	µg/dL
<i>FerroZine Colorimetric Assay</i>			
Unsaturated Iron Binding Capacity (UIBC)	311.3	125 - 345	µg/dL
<i>Direct determination with FerroZine</i>			
Iron Binding Capacity - Total (TIBC)	345.5	228-428	µg/dL
<i>Calculation</i>			
Transferrin Saturation Index (TSI)	<b>9.9 L</b>	16-45	
<i>Calculation</i>			

This is an electronically authenticated laboratory report.

Page 7 of 11



AMPATH  
 Central Reference Laboratory,  
 Door No. 1-100/1/CCH Nallagandla  
 Serilingampally  
 Hyderabad – 500019  
 040 6719 9977, www.ampath.com



MC-2751



**LABORATORY REPORT**

<b>NAME</b>	██████████	<b>REFERRED BY</b>	: .....	<b>VISIT NO</b>	: ██████████
<b>AGE</b>	: ██████████		████████████████████	<b>COLLECTED ON</b>	: ██████████
<b>GENDER</b>	██████████	<b>LAB MR#</b>	: ██████████	<b>RECEIVED ON</b>	██████████
<b>OP / IP / DG #</b>	:			<b>APPROVED ON</b>	: ██████████
				<b>REPORT STATUS</b>	: Final Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

Amfit Senior Citizen- Female

**SEROLOGY AND IMMUNOLOGY**

**Hepatitis B Surface antigen (HBsAg) - Spot Test** (Serum)

Hepatitis B Surface antigen (HBsAg) - Spot Test	Negative	Negative
<i>Immunochromatography</i>		

This is an electronically authenticated laboratory report.

Page 8 of 11



AmPath collaborates directly with UPMC, one of the top ten hospitals in the United States according to US News & World Report.

AmPath upholds rigorous standards for operational and clinical performance based on US hospital benchmarks. Test results have been furnished in adherence with these standards and under terms and conditions found on the reverse. For details, please email AmPath at [customersupport@ampath.com](mailto:customersupport@ampath.com) or call: 040 6719 9977.



**LABORATORY REPORT**

NAME : [REDACTED]	REFERRED BY : [REDACTED]	VISIT NO : [REDACTED]
AGE : [REDACTED]	[REDACTED]	COLLECTED ON : [REDACTED]
GENDER : [REDACTED]	LAB MR# : [REDACTED]	RECEIVED ON : [REDACTED]
OP / IP / DG # :		APPROVED ON : [REDACTED]
		REPORT STATUS : Final Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

Amfit Senior Citizen- Female

**BIOCHEMISTRY**

**Ferritin (Serum)**

Ferritin ECLIA	60.40	30-400	ng/mL
-------------------	-------	--------	-------

**Interpretation:**

Ferritin is iron storage protein. Determination of ferritin is necessary in iron deficiency anemia , monitoring iron therapy and in differential diagnosis of anemia

**Elevation levels seen in**

- Hemochromatosis
- Porphyria
- Rheumatoid arthrosis
- Leukaemia
- Hodgkin's lymphoma
- Liver disease
- Multiple blood transfusion
- Acute phase reactant
- Increased in all inflammatory condition

**Decreased level**

- Iron deficiency anemia

This is an electronically authenticated laboratory report.

Page 9 of 11





MC-2751

In collaboration with

**LABORATORY REPORT**

NAME : [REDACTED] REFERRED BY : ..... VISIT NO : [REDACTED]  
 AGE : [REDACTED] COLLECTED ON : [REDACTED]  
 GENDER : [REDACTED] LAB MR# : [REDACTED] RECEIVED ON : [REDACTED]  
 OP / IP / DG # : [REDACTED] APPROVED ON : [REDACTED]  
 REPORT STATUS : Final Report



Test Name	Result	Biological Ref. Interval	Unit
<b>Amfit Senior Citizen- Female</b>			
<b>CA 125 (Cancer Antigen 125) (Serum)</b>			
CA 125 ECLIA	8.75	< 35	U/mL

**Interpretation:**

CA 125 is a high molecular mass glycoprotein. Expresses by epithelial ovarian tumors and other pathological and normal tissues of mullerian duct origin. CA 125 found in a high percentage of ovarian tumors of epithelial origin and useful to monitor cancer treatment, to check for recurrence.

**Elevated values are found in cases of:**

Endometriosis, Ovarian cyst, early pregnancy, benign disease like pancreatitis, cirrhosis, hepatitis & other malignancies of endometrium, breast, gastrointestinal tract, lung etc.,

[REDACTED]  
 [REDACTED]  
 [REDACTED] **ist**

[REDACTED]  
 [REDACTED] (GY)  
**Consultant Microbiologist**

[REDACTED]  
 [REDACTED]  
**Consultant Pathologist**

**Disclaimer:**  
 1. All results released pertain to the specimen as received by the lab for testing and under the assumption that the patient indicated or identified on the bill/test requisition form is the owner of the specimen.  
 2. Clinical details and consent forms, especially in Genetic testing, histopathology, as well as wherever applicable, are mandatory to be accompanied with the test requisition form. The non-availability of such information may lead to delay in reporting as well as misinterpretation of test results. The lab will not be responsible for any such delays or misinterpretations thereof.  
 3. Test results are dependent on the quality of the sample received by the lab. In case the samples are preprocessed elsewhere (e.g., paraffin blocks), results may be compromised.  
 4. Tests are performed as per the schedule given in the test listing and in any unforeseen circumstances, report delivery may be affected.  
 5. Test results may show inter-laboratory as well as intra-laboratory variations as per the acceptable norms.  
 6. Genetic reports as well as reports of other tests should be correlated with clinical details and other available test reports by a qualified medical practitioner. Genetic counselling is advised in genetic test reports by a qualified genetic counsellor, medical practitioner or both.

AMPATH  
 Central Reference Laboratory,  
 Door No. 1-100/1/CCH Nallagandla  
 Serilingampally  
 Hyderabad – 500019  
 040 6719 9977, www.ampath.com



MC-2751



**LABORATORY REPORT**

NAME	: [REDACTED]	REFERRED BY	: [REDACTED]	VISIT NO	: [REDACTED]
AGE	: [REDACTED]			COLLECTED ON	: [REDACTED]
GENDER	: [REDACTED]	LAB MR#	: [REDACTED]	RECEIVED ON	: [REDACTED]
OP / IP / DG #	:			APPROVED ON	: [REDACTED]
				REPORT STATUS	: Final Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

**Amfit Senior Citizen- Female**

7. Samples will be discarded post processing after a specified period as per the laboratory's retention policy. Kindly get in touch with the lab for more information.

8. If accidental damage, loss, or destruction of the specimen is not attributable to any direct or negligent act or omission on the part of Ampath Labs or its employees, Ampath shall in no event be liable. Ampath lab's liability for a lack of services, or other mistakes and omissions, shall be restricted to the amount of the patient's payment for the pertinent laboratory services.

This is an electronically authenticated laboratory report.

Page 11 of 11



AmPath collaborates directly with UPMC, one of the top ten hospitals in the United States according to US News & World Report.

AmPath upholds rigorous standards for operational and clinical performance based on US hospital benchmarks. Test results have been furnished in adherence with these standards and under terms and conditions found on the reverse. For details, please email AmPath at [customersupport@ampath.com](mailto:customersupport@ampath.com) or call: 040 6719 9977.